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 Asthma is the most common inﬂ ammatory disease, and its prevalence is increasing throughout the 
world. Although corticosteroids are the most effec-
tive antiinﬂ ammatory agents for the treatment of 
asthma, 1 adult patients with asthma who currently 
smoke have relative steroid resistance. 2 Furthermore, 
their asthma becomes more severe and their lung 
function decreases more rapidly compared with non-
smoking patients with asthma. 3,4 Passive smoking (PS) 
also wors ens asthma symptoms and causes poor asthma 
control in both adults and children. 5,6 Exposure to 
parental smoking is related to exacerbation of asthma 
symptoms in children and can be a risk factor for the 
persistence of asthma in later childhood. 5 However, 
the molecular mechanisms of the effects of PS expo-
sure in childhood are currently unknown. 
 There are several possible mechanisms for cortico-
steroid resistance in asthma, including overexpression 
of proinﬂ ammatory transcription factors, phosphory-
lation of glucocorticoid receptors, and increases in the 
decoy glucocorticoid receptor- b . 7 Histone deacety-
lase (HDAC)-2 (HDAC2) has been shown to be a pre-
requisite molecule for corticosteroids to switch off 
activated inﬂ ammatory genes. Oxidative stress, such 
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Thoracic Society criteria, and the severity was deﬁ ned based on 
GINA (Global Initiative for Asthma) criteria. All had undergone a 
detailed evaluation to exclude as far as possible reversible factors 
such as poor adherence to therapy. 19 Subjects were classiﬁ ed into 
two groups (non-PS and PS). Exposure to PS was assessed on the 
basis of information reported by parents concerning their smoking 
habits. Cotinine levels in saliva or urine were measured to sup-
port their statements. The study was conducted in accordance 
with the amended Declaration of Helsinki (http://www.wma.net/en/
30publications/ 10policies/b3/) and was approved by the ethics 
committee of the Royal Brompton and Hareﬁ eld NHS Trust 
(Ethics approval number 08/H0708/3). All carers gave written 
informed consent, with age-appropriate assent from the children. 
 Nitric Oxide Measurement 
 Fraction of exhaled nitric oxide (F eno ) was measured accord-
ing to current guidelines. 20 A NIOX chemiluminescence analyzer 
at a ﬂ ow rate of 50 mL/s was used for analysis of F eno . 
 BAL and Macrophage Processing 
 BAL using ﬁ ber-optic bronchoscopy was performed under gen-
eral anesthetic, as described previously. 21 Cells were centrifuged 
and washed with Hanks’ balanced salt solution. Cytospins were 
prepared and stained with Diff-Quick for differential cell count. 
Cell viability was assessed using the Trypan blue exclusion method. 
BAL macrophages were isolated by plastic adhesion and were 
incubated in Macrophage Serum Free Medium (Invitrogen Ltd). 
 Cells 
 The human monocytic cell line U937 was purchased from 
LGC Standards. The cells were differentiated into an adherent 
macrophage-like morphology by exposure to PMA (50 ng/mL) 
for 48 h. 
 Cytokine Enzyme-Linked Immunosorbent Assay and 
Corticosteroid Sensitivity 
 CXCL8 concentrations were determined by sandwich enzyme-
linked immunosorbent assay (R&D Systems Europe Ltd). AMs or 
U937 cells were treated with dexamethasone (10  2 6 M), followed 
by TNF- a stimulation (10 ng/mL) for 2 h. The ability of dexa-
methasone to inhibit TNF- a -induced CXCL8 release was ana-
lyzed as a marker of corticosteroid sensitivity. 
 Thiobarbituric Acid Reactive Substances Assay 
 As a marker of oxidative stress, malondialdehyde (MDA) was 
measured as thiobarbituric acid reactive substances using a TBARS 
Assay Kit (Cayman Chemical Company). The levels were calcu-
lated using a standard curve. 
 Protein Extraction and Detection 
 Whole cell protein extracts were prepared using a radioimmu-
noprecipitation assay (RIPA) buffer as described previously. 8 Immu-
noprecipitation was conducted overnight with 2  m g of anti-HDAC2 
antibody (Sigma-Aldrich) in RIPA buffer. Cell lysates or immuno-
precipitates were analyzed by SDS-PAGE (Invitrogen Ltd) and 
detected with Western blot analysis by chemiluminescence (ECL 
Plus; GE Healthcare) as reported previously. 22 
 Total HDAC and HDAC2 Activity 
 To measure in-cell HDAC activity, cells were incubated with 
Fluor de Lys substrate (200  m M) for 1 h before cell lysis using 
as tobacco smoke, impairs HDAC2 function, leading 
to corticosteroid insensitivity in vitro and in vivo. 8-10 
HDAC2 expression and activity are reduced in the 
airways of, and alveolar macrophages (AMs) from, 
adults with severe asthma 11-13 and COPD. 14,15 Even 
more importantly, in patients with asthma who smoke, 
there is a signiﬁ cantly greater reduction of HDAC 
activity in bronchial biopsy specimens than in patients 
with asthma who do not smoke. 16 Further analysis 
revealed that oxidative stress such as tobacco smoke 
impairs HDAC2 via phosphoinositide-3-kinase (PI3K) 
 d (PI3K d )/Akt activation. 9,17 In this study, we tested 
the hypothesis that passive exposure to tobacco smoke 
is associated with reduced HDAC2 in AMs in children 
with severe and refractory asthma. 
 Materials and Methods 
 Reagents 
 3-(4,5-dimethylthiazol-2yr)-2-5-diphenyltetrazolium bromide, 
dimethyl sulfoxide, phorbol 12-myristate 13-acetate (PMA), the 
rabbit polyclonal HDAC-1 (HDAC1) antibody, and the mouse 
monoclonal HDAC2 antibody were purchased from Sigma-Aldrich. 
The rabbit polyclonal antibody to phospho-HDAC2 (Ser 394 ) and 
the mouse monoclonal antibody to  b -actin were obtained from 
Abcam. Protein A/G plus-agarose immunoprecipitation reagent 
was obtained from Santa Cruz Biotechnology, Inc. The mouse 
monoclonal anti-phospho-Akt1/PKB a (Ser 473 ) antibody and the 
rabbit polyclonal anti-Akt1/PKB a antibody were obtained from 
Millipore. Recombinant human tumor necrosis factor (TNF)- a 
was purchased from R&D Systems Europe Ltd. 
 Patients 
 Nineteen children with severe asthma were recruited for bron-
choscopy as part of the workup for severe, therapy-resistant 
asthma. 18 All the children were under regular follow-up at Royal 
Brompton Hospital. Asthma was diagnosed according to American 
 Manuscript received April 6, 2013; revision accepted August 1, 
2013. 
 Afﬁ liations: From the Airway Disease Section (Drs Kobayashi, 
Bossley, Gupta, Akashi, Tsartsali, Mercado, Barnes, Bush, and Ito), 
National Heart and Lung Institute, Imperial College London; and 
the Department of Respiratory Paediatrics (Drs Bossley, Gupta, 
Tsartsali, and Bush), Royal Brompton Hospital, London, England . 
 This study was presented previously at the American Thoracic Soci-
ety 2011 International Conference, May 13-18, 2011, Denver, CO. 
 Funding/Support:  This study was funded by the Wellcome Trust 
[WHRD_P31768 to Dr Barnes], London, England, and by the 
National Institute of Health Research Respiratory Disease Bio-
medical Research Unit at the Royal Brompton and Hareﬁ eld NHS 
Foundation Trust and Imperial College London (to Drs Bossley, 
Gupta and Bush). Dr Gupta is also the recipient of a British Med-
ical Association, James Trust Fellowship . 
 Correspondence to: Kazuhiro Ito, PhD, Airway Disease Section, 
National Heart and Lung Institute, Imperial College London, Guy 
Scadding Bldg, Royal Brompton Campus, Dovehouse St, London, 
SW3 6LY, England; e-mail: k.ito@imperial.ac.uk 
 © 2014 American College of Chest Physicians. This is a 
Wellcome-Trust-compliant open access article distributed under 
the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/3.0/). 
 DOI: 10.1378/chest.13-0835 
journal.publications.chestnet.org CHEST / 145 / 2 / FEBRUARY 2014  307 
PS group,  P  5 .60) and the Asthma Control Test (ACT) 
score (16.0 in the non-PS group vs 11.0 in the PS group, 
 P  5 .095) were relatively lower in the PS group, 
but there was no signiﬁ cant difference between the 
groups. The median number of years of exposure to 
PS in the PS group was 10.0. Consistent with infor-
mation reported by the patients’ parents, all subjects 
in the non-PS group had little or no cotinine detected, 
whereas the PS group showed relatively higher coti-
nine levels ( . 2  m g/L in urine or  . 0.2  m g/L in saliva). 
 BAL Analysis 
 There was no difference in total BAL cell counts 
or in numbers of macrophages and lymphocytes 
between the PS and the non-PS group. Subjects in 
the PS group had a relatively higher number of neutro-
phils than did non-PS group subjects, who had more 
eosinophils in BAL ﬂ uid (BALF) ( Table 2 ). In line with 
the increase of neutrophils, higher levels of CXCL8 
were found in BALF from the subjects in the PS group 
( Table 2 ), and furthermore, there was a positive cor-
relation between CXCL8 concentrations and the per-
centage of neutrophils ( r  5 0.71,  P  , .001). 
 HDAC2 Expression and Activity 
 In AMs, HDAC2 protein level normalized to  b actin 
protein expression was signiﬁ cantly lower in the PS 
group subjects compared with the non-PS group sub-
jects although HDAC1 protein expression normalized 
to  b actin protein was not different between PS and 
non-PS groups ( Figs 1A, 1B ). This reduction of HDAC2 
was conﬁ rmed by immunocytochemistry ( Fig 1C ) 
because positive brown signals in AMs were reduced 
RIPA buffer. Total HDAC activity was measured using the HDAC 
Fluorimetric Assay/Drug Discovery Kit (BIOMOL International, 
Inc). Immunoprecipitated (IP) HDAC2 was resuspended in HDAC 
assay buffer, and the activity was measured as indicated earlier. 
HDAC activity was expressed as micromolars of ﬂ uorescence 
standard provided in the kit. 
 Immunocytochemistry 
 HDAC2 in BAL macrophage cytospins was incubated with 
HDAC2 antibody (Santa Cruz Biothechnology, Inc; diluted 1:25). 
The HDAC2 was visualized using the VECTASTAIN kit (Vector 
Laboratories) as described previously. 8 
 Statistical Analysis 
 Statistical analysis between the non-PS group and the PS group 
was conducted with the Mann-Whitney  U test. If applicable in the 
in vitro test, the Student  t test was used for the comparison in 
paired groups. Correlation coefﬁ cients were calculated with the 
use of Spearman’s rank method. The results were expressed as 
medians (ﬁ rst and third quartiles) or mean   SEM. GraphPad 
Prism (GraphPad Software) was used for all statistical analyses, 
and  P values  , .05 were considered to be statistically signiﬁ cant. 
 Results 
 Patient Characterization 
 The characteristics of the patients are summarized 
in  Table 1 . All patients were receiving regular inhaled 
corticosteroids (median dose, 1,600  m g beclometha-
sone dipropionate equivalent in patients without PS 
and 1,600  m g in those with PS;  P  5 .78 ) and a long-
acting  b 2 -adrenoceptor agonist. There were no dif-
ferences in age, sex, FEV 1 % predicted, IgE level, 
atopic status, or use of any other medications between 
the non-PS and the PS groups. F eno (51.2 parts per 
billion [ppb] in the non-PS group vs 44.0 ppb in the 
 Table 1— Characteristics of Subjects 
Characteristics Non-Passive Smoking (n  5 10) Passive Smoking (n  5 9)
Age, y 9.5 (8.5-11.5) 10.0 (8.5-13.5)
Sex, male (female) 7 (3) 5 (4)
Lifetime exposure to passive smoking, y 0 10.0 (8.5-13.5)
FEV 1 % predicted 71.5 (68.0-78.5) 72.0 (51.5-89.0)
F eno , a ppb 51.2 (29.6-73.7) 44.0 (26.9-61.9)
ACT score 16.0 (10.5-17.5) 11.0 (8.5-14.5)
   15 5 8
Total IgE, IU/mL 386 (150-1,511) 355 (158-1,462)
Atopy b 8 c 7
Medication
 ICS, d  m g 1,600 (1,300-2,000) 1,600 (1,200-2,000)
 LABA 10 9
 LTRA 9 6
 Theophylline 2 2
Data are presented as median (ﬁ rst and third quartile) or No. unless indicated otherwise. There were no signiﬁ cant differences between the groups. 
ACT  5 Asthma Control Test; F eno  5 fraction of exhaled nitric oxide; ICS  5 inhaled corticosteroid; IU  5 International Units; LABA  5 long-acting 
 b 2 -adrenoceptor agonist; LTRA  5 leukotriene receptor antagonist; ppb  5 parts per billion.
 a Values in non-passive smoking represent medians of nine subjects.
 b Atopy was deﬁ ned as at least one positive speciﬁ c IgE radioallergosorbent assay (  0.34 kU/L).
 c Values in non-passive smoking represent No. out of nine subjects.
 d Beclomethasone dipropionate equivalent dose.
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 Akt1 and HDAC2 Phosphorylation 
 As shown in  Figure 2A , HDAC2 was highly phos-
phorylated in AMs of the PS group compared with 
the non-PS group. The levels of phosphorylation of 
Akt1, a surrogate marker of PI3K signaling activation, 
were also signiﬁ cantly increased by 2.4 fold in AMs 
of the PS group compared with the non-PS group 
( Fig 2B ) when normalized to total Akt1 protein expres-
sion. Furthermore, Akt1 phosphorylation levels were 
positively correlated with HDAC2 phosphorylation 
levels ( r  5 0.71,  P  , .001) ( Fig 2C ) and negatively 
correlated with HDAC2 activity ( r  5  2 0.54,  P  5 .018) 
( Fig 2D ). 
in the PS group. Although there was no signiﬁ cant 
difference in total HDAC activities in AMs between 
the two groups (median [first and third quartile]: 
30.6 [10.8-45.0] arbitrary ﬂ uorescence units [AFU]/ m g 
in the non-PS group vs 22.4 [13.8-28.6] AFU/ m g in the 
PS group), the activ ity of IP-HDAC2 was signiﬁ cantly 
reduced in the PS group compared with the non-PS 
group (5.8 [4.5-8.8] AFU/ m g in the non-PS group 
vs 3.7 [1.4-5.4] AFU/ m g in the PS group) ( Figs 1D, 1E ). 
Moreover, there was a positive correlation between 
HDAC2 expression and IP-HDAC2 activity ( r  5 0.59, 
 P  5 .0072) ( Fig 1F ), suggesting that the reduction in 
IP-HDAC2 activ ity was caused by the reduction of 
HDAC2 pro tein expression. 
 Table 2— Cell and CXCL8 Analysis in BAL 
Readout
Non-Passive Smoking (n  5 10) Passive  Smoking (n  5 9)  P Value
Cell Count,  3 10 3 /mL % of Total Cells Cell Count,  3 10 3 /mL % of Total Cells Cell Count,  3 10 3 /mL % of Total Cells
Total 370 (265-553) … 280 (205-403) … .2110 …
Macrophage 287 (196-389) 76.2 (70.5-78.0) 236 (326-162) 82.8 (81.3-85.9) .4967  .0030
Neutrophil 13.3 (9.2-23.1) 3.7 (3.0-4.5) 24.1 (12.7-34.4) 8.3 (6.5-9.5) .1333  .0021
Lymphocyte 55.2 (33.3-80.9) 14.7 (10.7-18.1) 10.9 (7.7-38.1) 5.0 (3.7-8.8) .0101   , .001
Eosinophil 11.6 (5.8-45.1) 4.0 (1.2-10.4) 2.9 (1.0-9.6) 1.6 (0.5-3.1) .0435  .1333
CXCL8, pg/ m g 
protein
0.11 (0.05-0.24) … 0.78 (0.27-1.40) … .0021 …
Data are presented as median (ﬁ rst and third quartile).
 Figure 1. Effects of PS on HDAC2 protein expression and activity in alveolar macrophages from 
children with severe asthma. A and B, Western blotting analysis of HDAC2 and HDAC1 protein 
expression, respectively, normalized to  b -actin expression. C, HDAC2 protein expression detected by 
immunocytochemistry (original magniﬁ cation  3 400). Results were representative of at least seven sub-
jects in each group. D, Total in-cell HDAC activity. E, Immunoprecipitated HDAC2 activity. F, Corre-
lation between HDAC2 protein expression and activity. Values in A, B, D, and E represent mean   SEM 
of 10 non-PS group subjects or nine PS group subjects. AFU  5 arbitrary ﬂ uorescence units; HDAC  5 
histone deacetylase; PS  5 passive smoking. 
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from subjects in the non-PS group. However, there 
was no signiﬁ cant inhibition in AMs from subjects in 
the PS group ( Fig 3A ). 
 Next, PMA-differentiated macrophage-like U937 
cells were exposed to BALF obtained from the 
PS group or the non-PS group. BALF from the PS group 
signiﬁ cantly increased Akt1 phosphorylation ( Fig 3B ) 
and HDAC2 phosphorylation ( Fig 3C ), and reduced 
IP-HDAC2 activity (336.6 [310.1-358.4] AFU/ m g in 
the non-PS group, 299.1 [277.0-316.7] AFU/ m g in 
the PS group) in U937 cells ( Fig 3D ). Pretreatment 
of dexamethasone (10  2 6 M) completely inhibited 
TNF- a -induced CXCL8 release in U937 exposed to 
BALF from subjects in the non-PS group, but the 
inhibitory action was limited in U937 exposed to BALF 
from PS group subjects ( Fig 3E ). Furthermore, the 
level of MDA, a marker of oxidative stress, was found 
to be signiﬁ cantly higher in BALF in the PS group 
than in the non-PS group ( Fig 3F ). 
 Discussion 
 This article reports that children with asthma who are 
passively exposed to tobacco smoke had the same 
molecular abnormalities leading to in vitro steroid resis-
tance as do adults who actively smoke. 8 Children with 
severe asthma who were exposed to PS had higher 
CXCL8 levels ( Table 2 ), in agreement with previous 
 Corticosteroid Sensitivity of CXCL8 Production 
in AMs 
 Dexamethasone at 10  2 6 M signiﬁ cantly inhibited 
TNF- a -induced CXCL8 production by 40% in AMs 
 Figure 2. Effects of PS on phosphorylation level of Akt1 and 
HDAC2 in alveolar macrophages from children with severe asthma. 
A and B, Phosphorylation levels of HDAC2-Ser 394 and Akt1, respec-
tively, normalized to total HDAC2 and Akt1 expression. Values 
represent means of 10 (in non-PS group) or nine (in PS group) 
subjects   SEM; C, Correlation between HDAC2 and Akt1 phos-
phorylation levels. D, Correlation between immunoprecipitated 
HDAC2 activity and phosphorylation level of Akt1. See Figure 1 
legend for expansion of abbreviations. 
 Figure 3. Effects of PS on corticosteroid sensitivity. A, Effects of Dex (10  2 6 M) on TNF- a -induced 
CXCL8 release in alveolar macrophages. B-D, Effects of BAL supernatant on (B) Akt1 phosphorylation 
levels, (C) HDAC2-Ser 394 phosphorylation, and (D), immunoprecipitated HDAC2 activity. E, Effects 
of Dex on TNF- a -induced CXCL8 release. PMA-differentiated U937 cells were preincubated over-
night with BAL ﬂ uid (BALF) (adjusted to 2  m g/mL of protein). F, MDA levels in BALF from non-PS 
and PS group subjects. Dex  5 dexamethasone; MDA  5 malondialdehyde; PMA  5 phorbol 12-myristate 
13-acetate; TNF  5 tumor necrosis factor. See Figure 1 legend for expansion of other abbreviations. 
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a single outlier, but when the outlier was removed, 
pAkt1 was still correlated with pHDAC2 ( r  5 0.66, 
 P  5 .0027). Thus, PI3K signaling activa tion by PS is 
likely one of the major causes of HDAC2 downregu-
lation in children with severe asthma 
 Oxidative stress, such as from tobacco smoke, may 
be an important factor in inducing corticosteroid insen-
sitivity. MDA is a product of lipid oxidation and an 
oxidative stress biomarker. 32 Previous reports showed 
that MDA was increased in several biologic ﬂ uids with 
exposure to cigarette smoke. 27,33,34 In this study, we also 
found a higher level of MDA in BALF from PS group 
subjects ( Fig 3F ). Importantly, when BALF from 
PS-exposed children was added to the macrophage-
type U937 cell line, the cells became corticosteroid 
insensitive, with increased phosphorylated Akt/HDAC2 
and reduced HDAC2 activity. Thus, high levels of oxi-
dative stress and their end products may induce cor-
ticosteroid insensitivity with dysfunction of HDAC2. 
In contrast, the F eno level was relatively lower in the 
PS group than in the non-PS group, which is consis-
tent with previous ﬁ ndings in adults. 35 
 In our study, more children with severe asthma 
who were exposed to PS had ACT scores of   15 when 
compared with patients with severe asthma who were 
not exposed to PS, indicating that the asthma of 
PS-exposed children was relatively poorly controlled, 
as reported previously. 36 However, there were no sig-
niﬁ cant differences in ACT scores between the groups, 
probably because of the relatively small number of 
patients. To strengthen our ﬁ ndings, more clinical 
outcomes are needed (eg, the effect of avoidance of 
PS in a longitudinal and much bigger group of chil-
dren with uncontrolled severe asthma). 
 Conclusions 
 We have demonstrated the molecular and cellular 
basis of an important adverse effect of PS exposure in 
children with severe asthma. PS exposure impairs 
HDAC2 function via PI3K activation, which may con-
tribute to a more steroid-resistant phenotype. Clearly, 
the avoidance of PS exposure is of paramount impor-
tance in all children, particularly those with severe 
asthma. 5 This study underscores on a molecular level 
the harm done to asthmatic children by parents who 
smoke. 
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reports, 14,23 and a higher neutrophil count and percent-
age in BALF ( Table 2 ), and the neutrophil percentage 
of total cell counts positively correlated with CXCL8 
concentration. Even more importantly, AMs from 
PS-exposed children with asthma exhibited cortico-
steroid insensitivity in the in vitro assay, manifest by 
the reduced effect of dexamethasone in suppressing 
TNF- a -induced CXCL8 production compared with 
children not exposed to PS with uncontrolled severe 
asthma. The prescribed corticosteroid dose was the 
same in the PS and the non-PS groups; therefore, 
inhaled corticosteroids were not a potential modiﬁ er 
of this response. To our knowledge, this is the ﬁ rst 
evidence that PS affects corticosteroid sensitivity in 
resident lung cells in children with severe asthma in 
vitro. Because there is no agreed-upon deﬁ nition of 
steroid sensitivity in children with asthma, we did not 
compare the in vitro steroid sensitivity and clinical 
response to steroids, and, thus, the clinical signiﬁ cance 
of our ﬁ ndings is speculative. However, we have shown 
previously that responses to steroids are reduced in 
children exposed to PS. 24 
 A reduction in HDAC activity, especially HDAC2, 
has been reported to cause corticosteroid insensi-
tivity. 8,25 We found that PS is associated with a lower 
expression of HDAC2, but not HDAC1, in AMs 
( Figs 1A-C ). AMs in BALF and peripheral lung tis-
sue from patients with COPD showed lower levels of 
HDAC2 expression with increasing disease severity; 
however, HDAC1 expression was not altered. 15 Fur-
thermore, in AMs from healthy cigarette smokers, 
HDAC2, but not HDAC1, expression was signiﬁ -
cantly decreased compared with those from healthy 
non smokers, 8 although in bronchial biopsy specimens 
obtained from adults with mild asthma, the expres-
sion levels of both HDAC1 and HDAC2 are slightly 
reduced. 11,12 These ﬁ ndings suggest that HDAC2 may 
be more sensitive to oxidative stress, especially cigarette 
smoking, than is HDAC1, as we reported pre viously. 25,26 
 The molecular mechanism of HDAC2 reduction 
has been studied extensively. Defects of HDAC2 
were induced by oxidative stress, leading to nitration 
and subsequent ubiquitination of HDAC2, 26 or car-
boxylation/oxidation. 27,28 A well-documented mecha-
nism is PI3K-dependent phosphorylation of HDAC2. 
Akt is phosphorylated through the PI3K d pathway 
during oxidative stress, 9,17 and activated Akt-dependent 
phosphorylation, mainly at Ser 394 , Ser 422 , and Ser 424 , 
may cause degradation and inactivation of HDAC2. 29-31 
In line with these previous reports, we found that 
PS increased phosphorylation of Akt1 ( Fig 2B ) and 
HDAC2-Ser 394 ( Fig 2A ). Akt1 phosphorylation was 
positively correlated with HDAC2 phosphorylation 
and negatively correlated with HDAC2 activity in AMs 
from children with severe asthma ( Figs 2C, 2D) . These 
observations seem to be driven by the presence of 
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